1
Purpose: Bevacizumab is a treatment option in patients with metastatic breast cancer.
2
Background: The presence of non-measurable disease is common in metastatic breast cancer.
3
Chemotherapy can produce excellent palliation for many patients with metastatic breast cancer.
4
Chemotherapy plays an important role in the management of metastatic breast cancer.
5
Eribulin is active and safe in heavily pre-treated metastatic breast cancer patients.
6
This therapy should be considered for selected patients with metastatic breast cancer.
7
Twenty of the 40 received neoadjuvant chemotherapy or chemotherapy for metastatic breast cancer.
8
Chemotherapy is offered to almost all patients with metastatic breast cancer.
9
This study evaluates these drugs in combination in metastatic breast cancer.
10
Capecitabine is an important drug in the therapeutic armamentarium for metastatic breast cancer.
11
Conclusions: HER-2-positive metastatic breast cancer is less responsive to any type of endocrine treatment.
12
Purpose: Gemcitabine-based chemotherapy remains one of the standards in management of metastatic breast cancer.
13
These new agents have substantial activity against metastatic breast cancer.
14
For metastatic breast cancer 12 drugs, six clinically active and six inactive, were tested.
15
Medroxyprogesterone acetate is an effective hormonal agent in the treatment of metastatic breast cancer.
16
Avastin was recommended in combination with paclitaxel for first-line treatment of metastatic breast cancer.
